Sign up to get each new magazine issue delivered to your inbox

Next Issue

November 2022

The measure of all the lifetime exposures to environmental and social factors is termed as the “exposome”. The interest in studying how these exposures relate to health has grown significantly, and international efforts are underway to use this information to guide health and environmental policies in the European Union. In next month’s issue, we take a look at how exposomic research is expected to aid drug development efforts and the drive for personalized medicine.


Also, in the backdrop of rising inflation across the globe, we will analyse the measures taken by contract manufacturing organisations to incorporate sustainability measures in their operations.


All this plus the latest trends and innovations in the pharma industry, as well as up-to-date analysis and insight from GlobalData experts.

EDITORIAL

Editor | Manasi Vaidya

Writers | Fiona Barry, Reynald Castaneda, Abi Millar, William Newton, Manasi Vaidya, Adam Zamecnik

Magazine Designer | Will Ingham
Graphic Designers | Anett Arc, Noemi Balint, Martina Labaiova, Tyrrell Lowe, Ashley McPherson
Lead Designer | John Hammond 

Publisher | Susanne Hauner

Advertising

Sales Manager | Tom McCormick
+44 207 8669440

Cover image credit: Ink Drop/ Shutterstock.com

Pharma Technology Focus is powered by H5mag

Read past issues of Pharma Technology Focus HERE

Copyright 2022 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | The promise of billion-dollar KRAS drugsGo to article: In this issueGo to article: ContentsGo to article:  Wek-tec Company InsightGo to article: CSafe GlobalGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: SHL Medical Company Insight Go to article: SHL MedicalGo to article: AgilentGo to article: CommentGo to article: The potential of virtual reality-based therapy for serious mental disordersGo to article: Brazil: an untapped market for big pharma manufacturingGo to article: More big wins for the AstraZeneca-Daiichi Sankyo collaborationGo to article: Dry powder inhalers carry potential to decrease greenhouse emissionsGo to article: Black participants severely underrepresented in global oncology studiesGo to article: Polio outbreak in New York state due to low vaccination coverageGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: SkyepharmaGo to article: In DepthGo to article: Exploring the promise of billion-dollar KRAS drugsGo to article: Nanorobots: small solutions to big delivery problemsGo to article: Foreign investments amplify the nucleic acid therapeutics fieldGo to article: Going beyond the mirage of complete skin clearance in psoriasisGo to article: As Russia’s clinical trials sector falls, Ukraine rebuildsGo to article: CMO Moves: Regulatory catalysts for drug manufacturing—SeptemberGo to article: Dr. Paul LohmannGo to article: BaxterGo to article: In DataGo to article: Top pharma companies best positioned to weather industry disruptionGo to article: Which pharma companies lead the way in artificial intelligence?Go to article: North America sees a hiring jump in big data roles in pharmaGo to article: Cloud computing mentions decrease in pharma filingsGo to article: EventsGo to article: Next issue